Advokatfirman Lindahl acts as an adviser in Abboxia’s merger with FrostPharma
Advokatfirman Lindahl represented the sellers of Abboxia in the strategic merger with FrostPharma. The two companies are now merging under the name of FrostPharma and will thus become one of the leading specialist pharmaceutical companies with the widest range of hospital drugs in the Nordic Region.
The merger combines FrostPharma’s commercial strength and strategic alliances with Abboxia’s development capacity, thus allowing more extensive supply of hospital medicines to Nordic healthcare providers.
The Lindahl team consisted of Svante Liljedahl, Olivia Sandin and Jannica Stefansson.
About FrostPharma and Abboxia
FrostPharma, which was founded in 2016, focuses on strategic partnerships and commercialisation of specialist pharmaceuticals in the Nordic market. Abboxia, which was founded in 2017, has developed several specialist medicines for the hospital segment in the Nordic Region.
Read more in the FrostPharma press release here.
Carousel items
-
Cases and transactions
12/11/2025
Lindahl advises Medivir on rights issue of approximately SEK 151 million
Lindahl has acted as legal adviser to Medivir AB (publ) in connection with the company's fully guaranteed rights issue of approximately SEK 151 million to finance a clinical trial of the drug candidate Fostrox.
-
Knowledge
12/9/2025
Avoid costly disputes – regulate jurisdiction clauses in your international agreements
Lindahl has extensive experience in handling cross-border disputes and can help you create clear, secure contracts. Contact our dispute resolution specialists for guidance on international jurisdiction and applicable law.
-
News articles
12/4/2025
Lindahl ranked in Chambers FinTech Guide 2026
Lindahl has been ranked in the Chambers FinTech Guide 2026: Sweden. Both the firm and partner Anna Wahlbom are ranked in Band 4.
-
Portraits
11/7/2025
Capital markets and public M&A at Lindahl: Expertise, working environment and range
Read about how Monica Lagercrantz and Lindahl's experts in capital markets and public M&A support companies with stock exchange listings, new share issues and ongoing advice – with expertise, range and a working environment that makes a difference.
-
Read more news and insights?
